LIB Therapeutics Announces Lerodalcibep Abstracts Accepted for Presentation at the 92nd European Atherosclerosis Society Congress
23 Mayo 2024 - 8:00AM
Business Wire
LIB Therapeutics Inc. (LIB), a privately-held, late-stage
biopharmaceutical company advancing Lerodalcibep, a novel,
LDL-cholesterol lowering, third-generation PCSK9 inhibitor, today
announced acceptance of two abstracts from the recently completed
Phase 3 registration-enabling LIBerate program for presentation at
the 92nd European Atherosclerosis Society Congress in Lyon, France
on May 26-29, 2024.
- Oral Presentation: Science at a Glance Session - Late-Breaking
Lipids; Moderated Poster Station 8; “Randomized, Open-Label, Study
Comparing Efficacy and Safety of Lerodalcibep to Inclisiran in
Patients with CVD or at High Risk for CVD Requiring Additional
LDL-Cholesterol Reduction”; presented by Prof. Ulrich Laufs
(Germany), May 28, 1:30 PM – 1:37 PM CET
- Oral Presentation: Late Breaker Session 2 - New therapeutic
agents; René Leriche Hall - Forum 2; “Long Term Efficacy and Safety
of Lerodalcibep in Patients with Atherosclerotic Cardiovascular
Disease (LIBerate-CVD)”; presented by Dr. Evan Stein, May 29, 11:00
AM – 11:15 AM CET
About Lerodalcibep
Lerodalcibep is a novel, potent, small binding protein,
third-generation PCSK9 inhibitor, and has been developed as a more
convenient, once-monthly, single subcutaneous injection with
long-ambient stability. In clinical trials, Lerodalcibep has
demonstrated sustained LDL-C reductions and is expected to expand
treatment options for the millions of patients around the world
with atherosclerotic cardiovascular disease (ASCVD), and those at
very high and high risk for ASCVD, including the 30 million
individuals with more severe inherited high-cholesterol called
familial hypercholesterolemia (FH).
The global Phase 3 LIBerate program enrolled a diverse
population of over 2,700 patients with CVD, without CVD at very
high and high risk for CVD, including heterozygous and homozygous
familial hypercholesterolemia. Lerodalcibep was dosed once-monthly
for up to 52 weeks in these key registration-enabling,
placebo-controlled trials, and over 2,400 patients have continued
in the 72-week open-label extension trial. LIB is preparing a
biologics license application (BLA) for Lerodalcibep and plans for
regulatory submission in 2024.
About LIB Therapeutics Inc.
LIB Therapeutics is a privately-held, late-stage
biopharmaceutical company dedicated to bringing Lerodalcibep to the
millions of patients with cardiovascular disease and to the 30
million individuals with familial hypercholesterolemia (FH), who
require additional large reductions in low density
lipoprotein-cholesterol (LDL-C), despite maximally tolerated
statins and other lipid lowering agents, to achieve LDL-C
goals.
For more information, please visit: www.libtherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523001053/en/
Ingrid Choong, PhD Chief Business Officer
ichoong@libtherapeutics.com